Ocugen, Inc.
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, we are advancing vaccine research in the fight against COVID-19, and our work in cell therapy is aimed at orthopedic disease for which no effective treatment options currently exist.
NEWS
Pennsylvania-based Ocugen has struck a deal to sell 100 million doses of a COVID-19 vaccine India’s Bharat Biotech in the United States later this year.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Ocugen announced this morning that its mid-stage combination treatment hit its primary endpoint of tolerability in a proof-of-concept trial.
JOBS
IN THE PRESS